Proteomic analysis of eIF-5A in lung adenocarcinomas

被引:45
作者
Chen, G
Gharib, TG
Thomas, DG
Huang, CC
Misek, DE
Kuick, RD
Giordano, TJ
Iannettoni, MD
Orringer, MB
Hanash, SM
Beer, DG
机构
[1] Univ Michigan, Sch Med, Dept Surg, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA
[4] Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA
关键词
eukaryotic initiation factor-5A; lung adenocarcinoma; lymphocyte; K-ras; p53; two-dimensional gel electrophoresis;
D O I
10.1002/pmic.200390063
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
We examined the eIF-5A protein expression in 93 lung adenocarcinomas and 10 uninvolved lung samples using quantitative two-dimensional polyacrylamide gel electrophoresis (2-D PAGE) analysis with identification by mass spectrometry and 2-D Western blots. The same tissue samples were examined for the eIF-5A mRNA expression using oligonucleotide microarrays, and the cellular localization of the eIF-5A protein was examined using immunohistochemical analysis on tissue arrays. Higher eIF-5A protein expression was present in tumors showing poor differentiation, 12/13(th) codon K-ras mutations, p53 nuclear accumulation, and tumors with positive lymphocytic response. The eIF-5A mRNA was also significantly increased in lung adenocarcinomas compared to normal lung, but the eIF-5A protein expression was not correlated to its mRNA levels indicating that the increase in the eIF-5A protein expression in lung tumors is post-transcriptionally/translationally/post-transiationally regulated. Patients having a higher eIF-5A protein expression showed a relatively poorer survival suggesting the use of eIF-5A as prognostic marker in lung adenocarcinoma. Moreover, the investigation on agents that inhibit eIF-5A function is encouraged.
引用
收藏
页码:496 / 504
页数:9
相关论文
共 30 条
  • [1] Blocking oncogenic Ras signaling for cancer therapy
    Adjei, AA
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (14): : 1062 - 1074
  • [2] Gene-expression profiles predict survival of patients with lung adenocarcinoma
    Beer, DG
    Kardia, SLR
    Huang, CC
    Giordano, TJ
    Levin, AM
    Misek, DE
    Lin, L
    Chen, GA
    Gharib, TG
    Thomas, DG
    Lizyness, ML
    Kuick, R
    Hayasaka, S
    Taylor, JMG
    Iannettoni, MD
    Orringer, MB
    Hanash, S
    [J]. NATURE MEDICINE, 2002, 8 (08) : 816 - 824
  • [3] BENNE R, 1978, J BIOL CHEM, V253, P3070
  • [4] Inhibition of HIV-1 replication in lymphocytes by mutants of the Rev cofactor eIF-5A
    Bevec, D
    Jaksche, H
    Oft, M
    Wohl, T
    Himmelspach, M
    Pacher, A
    Schebesta, M
    Koettnitz, K
    Dobrovnik, M
    Csonga, R
    Lottspeich, F
    Hauber, J
    [J]. SCIENCE, 1996, 271 (5257) : 1858 - 1860
  • [5] INDUCED GENE-EXPRESSION OF THE HYPUSINE-CONTAINING PROTEIN EUKARYOTIC INITIATION-FACTOR 5A IN ACTIVATED HUMAN T-LYMPHOCYTES
    BEVEC, D
    KLIER, H
    HOLTER, W
    TSCHACHLER, E
    VALENT, P
    LOTTSPEICH, F
    BAUMRUKER, T
    HAUBER, J
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (23) : 10829 - 10833
  • [6] Caraglia M, 1999, ADV EXP MED BIOL, V472, P187
  • [7] Modulation of molecular mechanisms involved in protein synthesis machinery as a new tool for the control of cell proliferation
    Caraglia, M
    Budillon, A
    Vitale, G
    Lupoli, G
    Tagliaferri, P
    Abbruzzese, A
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 2000, 267 (13): : 3919 - 3936
  • [8] Discordant protein and mRNA expression in lung adenocarcinomas
    Chen, GA
    Gharib, TG
    Huang, CC
    Taylor, JMG
    Misek, DE
    Kardia, SLR
    Giordano, TJ
    Iannettoni, MD
    Orringer, MB
    Hanash, SM
    Beer, DG
    [J]. MOLECULAR & CELLULAR PROTEOMICS, 2002, 1 (04) : 304 - 313
  • [9] Chen GA, 2002, CLIN CANCER RES, V8, P2298
  • [10] Chen JD, 1996, MOL CELL BIOL, V16, P2445